Abstract: The present invention relates to methods for identifying markers for systemic sclerosis (also referred to as scleroderma; SSc) and the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices, and test kits which comprise these markers, and also to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc subgroups.

Abstract: The present invention relates to a method for the diagnosis and/or risk stratification of neuromyelitis optica (abbreviated NMO), wherein a determination from a body sample of a patient/test subject is performed by means of artificial aquaporin-4 peptides. The invention further relates to a kit and to new artificial aquaporin-4 peptides as such.

Abstract: The present invention relates to a method for the diagnosis and/or risk stratification of neuromyelitis optica (abbreviated NMO), wherein a determination from a body sample of a patient/test subject is performed by means of artificial aquaporin-4 peptides. The invention further relates to a kit and to new artificial aquaporin-4 peptides as such.

Abstract: The present invention relates to a novel method for identifying specific marker sequences for diagnosis of prostate cancer and/or for prognosis in prostate cancer, and to the use of the specific marker sequences identified with the aid of this method.

Abstract: The present invention relates to a method for identifying marker sequences for breast cancer, the marker sequences identified with the aid of this method and diagnostic use thereof, diagnostic devices containing marker sequences for breast cancer, in particular an arrangement and a protein array, and use thereof. The invention also relates to method for the screening of potential active agents for the treatment and prevention of breast cancer by means of these marker sequences.

Abstract: The invention relates to novel marker sequences for multiple sclerosis and to the use thereof in diagnosis as well as to a method for screening potential active ingredients for multiple sclerosis diseases the marker sequences. The invention further relates to a diagnostic device containing such marker sequences for multiple sclerosis, especially to a protein biochip and the use thereof.

Abstract: The present invention relates to new marker sequences for multiple sclerosis and the diagnostic use thereof together with a method for screening of potential active substances for multiple sclerosis by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for multiple sclerosis, in particular a protein biochip and the use thereof.

Abstract: The present invention relates to new marker sequences for rheumatoid arthritis and the diagnostic use thereof together with a method for screening of potential active substances for rheumatoid arthritis by means of these marker sequences. Furthermore, the invention relates to a diagnostic device containing such marker sequences for rheumatoid arthritis, in particular a protein biochip and the use thereof.

Abstract: The invention relates to an arrangement of proteins containing at least one cDNA-expression library and to the use thereof as a protein-biochip, in particular for validating binding agents and protein binding agents and to a method for determining in a simultaneous manner quantitative variables.

Abstract: The invention relates to regulator T-cells containing galectins, in particular, the use thereof as markers and for the therapy and diagnosis of diseases, in particular, of allergies and autoimmune diseases, in particular rheumatoid arthritis, multiple sclerosis or Crohn's disease, chronic inflammation, asthma, immune deficiency diseases, AIDS, transplant rejection, cancer diseases and diabetes.

Abstract: The present invention relates to a method and to a system (100) for predicting the primary structure of biopolymers, especially of proteins and peptides, in which at least two algorithms or the results of at least two algorithms and/or of bioinformatic analyses are combined in order to increase the significance of the results. The system (100) comprises a user interface (UI) for configuring and outputting the results as well as a database interface (DBI) with the databases (DB1, DB2) containing, for example, known amino acid sequences, and with which algorithms for bioinformatic sequences can be actuated.

Abstract: The present invention relates to a method for elucidating the primary structure of biopolymers, in which a biopolymer to be investigated is cleaved into fragments and, after that, subjected to a mass spectrometric analysis (20) resulting in mass spectra being obtained, and in which known algorithms, are used for a first sequence analysis (30) of the fragments in order to determine a primary structure of the biopolymer using the mass spectra. The mass spectra are classified in dependence on results of the first sequence analysis (30), resulting in at least one first spectrum class, to which a known biopolymer can be assigned, and one second spectrum class, to which no known biopolymer can be assigned, being obtained. A further analysis (50) of mass spectra of the second spectrum class is carried out in dependence on the known biopolymer.